Translational Cancer Research

Scope & Guideline

Exploring the latest breakthroughs in cancer research.

Introduction

Welcome to the Translational Cancer Research information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of Translational Cancer Research, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN2218-676x
PublisherAME PUBLISHING COMPANY
Support Open AccessNo
CountryHong Kong
TypeJournal
Convergefrom 2012 to 2024
AbbreviationTRANSL CANCER RES / Transl. Cancer Res.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressFLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA

Aims and Scopes

Translational Cancer Research is dedicated to bridging the gap between basic cancer research and clinical applications, striving to improve patient outcomes through innovative research and methodologies.
  1. Molecular Mechanisms of Cancer:
    The journal focuses on the molecular and cellular mechanisms underlying cancer development and progression, including studies on gene expression, signaling pathways, and tumor microenvironment interactions.
  2. Biomarker Discovery and Validation:
    There is a strong emphasis on identifying and validating new biomarkers for cancer diagnosis, prognosis, and treatment response, utilizing bioinformatics, genomics, and proteomics approaches.
  3. Therapeutic Strategies:
    Research articles often explore novel therapeutic strategies, including targeted therapies, immunotherapies, and combination treatments, assessing their effectiveness and safety through clinical trials and preclinical studies.
  4. Clinical Research and Trials:
    The journal publishes findings from clinical studies aimed at improving treatment protocols and understanding patient responses, including retrospective analyses, meta-analyses, and randomized controlled trials.
  5. Translational Approaches:
    A unique contribution of the journal is its commitment to translational research, integrating laboratory findings with clinical practices to enhance therapeutic outcomes in cancer patients.
Recent trends within Translational Cancer Research indicate a shift towards several emerging themes that reflect the current landscape of cancer research and treatment strategies.
  1. Immunotherapy and Combination Treatments:
    There is a growing emphasis on the exploration of immunotherapy, particularly its combination with other treatment modalities, showcasing the potential for enhanced efficacy in cancer therapies.
  2. Bioinformatics and Computational Biology:
    The application of bioinformatics tools for data analysis, particularly in genomics and proteomics, is gaining traction as researchers seek to identify novel biomarkers and therapeutic targets.
  3. Cancer Microenvironment Studies:
    Research focusing on the tumor microenvironment, including immune cell interactions and extracellular matrix components, is increasingly relevant as it plays a crucial role in tumor progression and therapy resistance.
  4. Liquid Biopsies and Non-Invasive Diagnostics:
    The emergence of liquid biopsy techniques for cancer detection and monitoring is a significant trend, reflecting a shift towards less invasive diagnostic methods that provide real-time insights into tumor dynamics.
  5. Personalized Medicine Approaches:
    There is an increasing trend towards personalized medicine, with studies focusing on tailoring treatments based on individual genetic profiles and tumor characteristics to improve patient outcomes.

Declining or Waning

As the field of cancer research evolves, certain themes within Translational Cancer Research have shown a decline in frequency or prominence. This section highlights those waning scopes.
  1. Traditional Chemotherapy Studies:
    Research focused solely on traditional chemotherapy regimens without the integration of newer modalities such as immunotherapy or targeted therapy has decreased, reflecting a shift towards more innovative treatment approaches.
  2. Basic Science Studies without Clinical Relevance:
    There is a noticeable waning interest in basic science studies that do not directly translate to clinical applications or patient outcomes, as the focus shifts towards more applicable research.
  3. Single-Agent Drug Trials:
    The frequency of publications centered on single-agent drug trials has diminished, as combination therapies and personalized medicine strategies gain more attention in the quest for effective cancer treatments.

Similar Journals

Journal of Cancer

Elevating cancer research to new heights.
Publisher: IVYSPRING INT PUBLISSN: 1837-9664Frequency: 12 issues/year

Journal of Cancer is a premier, peer-reviewed academic journal published by IVYSPRING INTERNATIONAL PUBLISHING that focuses on advancing the field of oncology. With an impact factor reflecting its significant contributions, this journal ranks in the 80th percentile of medical journals pertaining to oncology, positioning it at #79 out of 404 in Scopus. Since its inception in 2010, the journal has embraced an Open Access model, ensuring that groundbreaking research reaches a global audience without barriers. Based in Australia, the journal addresses a wide array of topics within cancer research, catering to researchers, healthcare professionals, and students committed to enhancing their understanding of the complexities of cancer. Amidst evolving challenges in oncology, the Journal of Cancer serves as a vital platform for disseminating innovative findings, fostering collaboration, and promoting informed decisions that can lead to improved cancer outcomes worldwide.

NEOPLASMA

Fostering Collaboration in Oncology Research
Publisher: AEPRESS SROISSN: 0028-2685Frequency: 6 issues/year

NEOPLASMA is a prominent journal published by AEPRESS SRO, dedicated to the multifaceted field of oncology and cancer research. Since its inception in 1957, this esteemed publication has served as a vital platform for advancing the understanding of neoplastic diseases, disseminating high-quality research findings that contribute to clinical and laboratory advancements. Operating under a robust framework of peer review, NEOPLASMA holds significant credibility, as evidenced by its Q2 ranking in the Medicine (miscellaneous) category and Q3 rankings in both Cancer Research and Oncology for 2023. Furthermore, with an ISSN of 0028-2685 and E-ISSN 1338-4317, the journal fosters accessibility to valuable scientific content despite the absence of open access options. Positioned in Bratislava, Slovakia, NEOPLASMA continues to attract a global readership, making substantial contributions to the fields of biochemistry, genetics, and molecular biology as highlighted by its Scopus rankings. This journal is essential reading for researchers, professionals, and students looking to stay abreast of the latest developments in cancer research and treatment strategies.

Cancers

Transforming cancer knowledge into impactful solutions.
Publisher: MDPIISSN: Frequency: 24 issues/year

Cancers is a leading peer-reviewed journal published by MDPI, dedicated to advancing the field of oncology and cancer research. Established in 2009 and based in Switzerland, this Open Access journal provides a platform for the rapid dissemination of high-quality research findings, reviews, and clinical studies related to all aspects of cancer biology and treatment. With an impressive impact factor and recognized as Q1 in Oncology and Q2 in Cancer Research for 2023, Cancers strives to foster a collaborative environment among researchers, healthcare professionals, and students seeking to deepen their knowledge and understanding of cancer. The journal’s commitment to accessibility and its broad scope make it an invaluable resource for anyone passionate about combating cancer and improving patient outcomes. For more information and to access its diverse publications, visit the journal’s website.

ONCOLOGY RESEARCH

Pioneering Insights in Oncology and Medicine
Publisher: TECH SCIENCE PRESSISSN: 0965-0407Frequency: 6 issues/year

ONCOLOGY RESEARCH, published by TECH SCIENCE PRESS, is a vital academic journal dedicated to the rapidly evolving field of oncology. With its ISSN 0965-0407 and E-ISSN 1555-3906, the journal serves as a key resource for researchers, clinicians, and academicians committed to advancing cancer research and treatment strategies. Operating without an Open Access model, ONCOLOGY RESEARCH provides high-quality, peer-reviewed articles that cover diverse topics within cancer research, medicine, and oncology, with its 2023 Scopus ranking placing it in the Q3 quartile. The journal's commitment to facilitating rigorous scientific discourse is evident in its historical breadth, with a publishing history dating back to 1992. ONCOLOGY RESEARCH is not only significant for the academic community but also plays a critical role in fostering new insights and approaches in the fight against cancer, making it a must-read for those involved in this critical area of study.

Journal of Cancer Research and Therapeutics

Elevating the dialogue in oncology and radiology.
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 0973-1482Frequency: 12 issues/year

The Journal of Cancer Research and Therapeutics is a prominent peer-reviewed platform dedicated to advancing scientific knowledge in the fields of oncology, radiology, and therapeutic interventions. Published by Wolters Kluwer Medknow Publications in India, this journal has been an essential resource for researchers and professionals since its inception in 2005, with a convergence of findings through to 2024. Although classified within the Q3 quartile across multiple relevant categories in the 2023 rankings, the journal maintains a significant impact in the fields of medicine, particularly in oncology and radiology, as evidenced by its Scopus rankings. The journal aims to disseminate high-quality research, case studies, and clinical trials that contribute to understanding and improving cancer treatments and patient care. With its accessibility to a global audience, the Journal of Cancer Research and Therapeutics plays a pivotal role in fostering dialogue and collaboration among researchers and healthcare professionals dedicated to combating cancer.

MOLECULAR CANCER RESEARCH

Transforming Research into Revolutionary Treatments
Publisher: AMER ASSOC CANCER RESEARCHISSN: 1541-7786Frequency: 12 issues/year

MOLECULAR CANCER RESEARCH, published by the American Association for Cancer Research, stands as a pivotal journal in the fields of cancer research, molecular biology, and oncology. With an impressive impact factor and recognized as a Q1 journal in its respective categories for 2023, it serves as an essential resource for researchers, professionals, and students aimed at advancing our understanding of cancer mechanisms and therapies. The journal, identified by the ISSN 1541-7786 and E-ISSN 1557-3125, provides a platform for cutting-edge research and clinical applications, emphasizing innovation and collaboration within the scientific community. With its focus on high-quality, peer-reviewed articles, MOLECULAR CANCER RESEARCH is vital for anyone looking to stay abreast of significant advancements in cancer biology and treatment strategies. For more details and to access the journal's content, please visit the publisher's link.

CANCER LETTERS

Transforming discoveries into therapeutic realities.
Publisher: ELSEVIER IRELAND LTDISSN: 0304-3835Frequency: 28 issues/year

Cancer Letters, a leading journal published by Elsevier Ireland Ltd, is dedicated to advancing the field of oncology and cancer research. With a rich history that spans from 1975 to 2024, this esteemed journal has established itself as a vital resource within the scientific community, holding a prestigious Q1 status in both Cancer Research and Oncology categories as of 2023. With an impressive ranking of #26/404 in Medicine _ Oncology and #19/230 in Biochemistry, Genetics and Molecular Biology _ Cancer Research, Cancer Letters sits in the top percentiles of its field, reflecting its high impact and relevance. Although it does not currently offer open access, the journal remains committed to disseminating paramount research findings, innovative methodologies, and critical reviews that inform and enhance ongoing studies in cancer therapeutics and patient care. Researchers, professionals, and students alike will find invaluable insights into the latest developments and discoveries in cancer research through the pages of Cancer Letters.

INTERNATIONAL JOURNAL OF CANCER

Exploring the frontiers of cancer science and treatment.
Publisher: WILEYISSN: 0020-7136Frequency: 24 issues/year

INTERNATIONAL JOURNAL OF CANCER, published by Wiley, stands as a premier platform for the dissemination of cutting-edge research in the fields of cancer research and oncology. With an impressive impact factor reflecting its rigorous peer-review process and significant contribution to the scientific community, this journal is categorized in Q1 for both Cancer Research and Oncology as of 2023. It boasts notable rankings, being placed 38th among 404 journals in Medicine - Oncology and 32nd among 230 in Biochemistry, Genetics, and Molecular Biology - Cancer Research, positioning it within the 90th and 86th percentiles, respectively. Since its inception in 1966 and continuing to 2024, the journal has played a pivotal role in advancing our understanding of cancer biology, treatment modalities, and innovative therapeutic approaches. While it operates under a subscription model, the journal is committed to making valuable research accessible to a broader scientific audience. Researchers, professionals, and students alike will find the INTERNATIONAL JOURNAL OF CANCER an essential resource for staying abreast of the latest advancements in cancer science.

NATURE REVIEWS CANCER

Shaping Tomorrow's Cancer Solutions Today
Publisher: NATURE PORTFOLIOISSN: 1474-175XFrequency: 12 issues/year

NATURE REVIEWS CANCER, a premier journal published by NATURE PORTFOLIO, stands as a cornerstone in the field of oncology, focusing on delivering high-quality, comprehensive reviews that shape our understanding of cancer biology, prevention, and treatment. With an impressive impact in the academic community, it ranks Q1 in both Cancer Research and Oncology categories as of 2023, further denoted by a remarkable Scopus ranking as the top journal in Cancer Research and second in Oncology. This ensures that published articles not only set the standard for scientific excellence but also drive significant advancements in cancer research methodologies and practices. The journal's targeted audience, including researchers, practitioners, and students, will greatly benefit from its insightful analyses and interdisciplinary approach. While it operates under a traditional subscription model, the rich content and vast expertise presented in its articles foster a global dialogue on cancer-related issues, making it an essential resource for anyone dedicated to the advancement of cancer science.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Unlocking the secrets of cancer biology and therapy.
Publisher: BMCISSN: Frequency: 1 issue/year

The JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, published by BMC, is a leading open-access journal dedicated to advancing the field of cancer research and oncology. Since its inception in 1982, this esteemed journal has fostered innovation and collaboration in the scientific community, as evidenced by its outstanding impact factor and position in the Q1 quartile for both Cancer Research and Oncology categories in 2023. With a proud commitment to disseminating high-quality research, the journal operates under an open-access model, ensuring that findings are readily accessible to researchers, healthcare professionals, and students worldwide. The journal has established a distinguished reputation, ranking 23rd out of 404 in Medicine oncology and 16th out of 230 in Biochemistry, Genetics, and Molecular Biology (cancer research), showcasing its importance and influence in guiding the future of cancer treatment and research. With the aim of bridging experimental and clinical research, this journal invites submissions that push the boundaries of our understanding of cancer biology and therapy.